ABSTRACT. Meta-analyses have revealed many positive associations between gene variants and susceptibility to chronic obstructive pulmonary disease (COPD). However, some of those positive results may be false positives. Therefore, we investigated the genetic polymorphisms associated with COPD risk and determined their diagnostic value. We extracted the odds ratio (OR) and 95% confidence interval for each polymorphism from published meta-analyses concerning gene variants and COPD susceptibility in October 2014, subsequently we calculated false-positive report probabilities (FPRPs) for statistically significant associations (P value < 0.05). We determined the diagnostic value of the true positive polymorphisms of COPD using the Meta-DiSc software. Twenty-five gene polymorphisms were significantly associated with COPD risk. The FPRP test results were as follows: 1) when the prior probability was 0.001 and the OR was 1.5, ADAM33 rs612709, CHRNA3/5 rs1051730, CHRNA3/5 rs8034191, CHRNA3/5 rs16969968, and TGFB1 rs1800470 were truly associated with COPD risk (FPRP < 0.2); 2) when the prior probability was 0.000001 and the OR was 1.5, all the variants except TGFB1 rs1800470 remained noteworthy; and 3) when the probability was 0.000001 and the OR was 1.2, ADAM33 rs612709 and CHRNA3/5 rs1051730 remained true positives. Unfortunately, the results of the diagnostic accuracy meta-analyses suggested that none of the variants had high value for COPD diagnosis.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is considered to be both preventable and treatable. COPD involves continual and progressive air current limitation and intensive chronic inflammatory response owing to toxic particles and gases in the respiratory tract and lungs. According to Halbert et al. (2006) , the prevalence of COPD is approximately 10% in people older than 40 worldwide. In the Chinese population, 8.2% suffer from COPD [95% confidence interval (CI) = 7.9-8.6] (men, 12.4%; women, 5.1%) (Zhong et al., 2007) . In 2010, COPD led to the death of approximately three million individuals, and was ranked third as the cause of death globally (Lozano et al., 2012) . In 2006, the cost of COPD per patient ($1963.80 ) demanded 40% of the family's economic income ($4849.80) in China (Fang et al., 2011) . The etiology of COPD involves complicated genetic and environmental factors, the most crucial of which is tobacco consumption. However, although 90% of COPD cases are attributed to longterm smoking, only one quarter of smokers suffer from COPD. Also, smokers with comparable smoking histories demonstrate marked heterogeneity in lung function (Løkke et al., 2006) . Furthermore, COPD generally occurs in smokers, who have a family history of chronic obstructive respiratory tract diseases, may also be associated with the risk of COPD. Each year, more studies indicate certain candidate genes that are involved in COPD risk, such as the ADAM family of genes (A disintegrin and metalloprotease), TGFB1 (transforming growth factor-b1), and CHRNA3/5 (a-neuronal nicotinic acetylcholine receptor subunit).
Unfortunately, each separate study has a distinct sample size, which may induce conflicting outcomes with lower statistical powers. Another deficiency of genetic epidemiology studies is their lack of reproducibility. A few studies have attempted to find a formerly published statistically significant result on a genetic mutation, but have failed owing to "false-positive" reports (Ioannidis et al., 2001; Morgan et al., 2007) . Hence, meta-and pooled analyses have been employed to combine both positive and negative results from separate studies and weigh these results by their precision.
Previous meta-analyses have reported over 30 single nucleotide polymorphisms (SNPs) associated with COPD susceptibility. However, for molecular epidemiology studies, Wacholder et al. (2004) suggested that use of the P value alone is inadequate for evaluating statistical significance. The prior probability of the association between the genetic variant and the disease is real, and the statistical power of the test is also required. They invented a method to assess the false-positive report probability (FPRP), which determines whether a result is a true positive (noteworthy) or not. Because three parameters are required to adequately evaluate a medical diagnostic test (sensitivity, specificity, and the predictive value of a positive test), three analogous parameters are required to adequately evaluate statistical tests on the associations between genetic variants and COPD. The P value is analogous to 1 minus specificity. The study power is analogous to sensitivity. Nevertheless, in medical diagnostics, the predictive values of positive tests can still be low, while specificity and sensitivity are high, because positive diagnostic tests mainly produce false-positive results when the condition is rare. This situation is also crucial in evaluating statistical tests of exposure-disease hypotheses, because when the prior probability that a hypothesized association is true is small, a statistically significant result is probably a false positive. The FPRP, defined as "the probability of no association given a statistically significant finding", is another analogous parameter to 1 minus the predictive value of a positive test. Therefore, it is actually the FPRP that illustrates how probable the hypothesis is, instead of the P value. In brief, meta-and pooled analyses can also contain false-positive results. However, there has been no FPRP analysis on the associations between genetic variants and COPD. Moreover, among the true-positive results the diagnostic value is unclear. We performed this study to evaluate the validity of published associations and the diagnostic value of the relevant SNPs.
MATERIAL AND METHODS
All potential meta-and pooled analyses that had investigated the association between genetic variants and COPD risks were identified in October 12, 2014. We used the PubMed, Embase, China National Knowledge Internet, and Wanfang databases. The following search terms were used for the literature search: "COPD" or "chronic obstructive pulmonary disease", "polymorphism" or "polymorphisms" or "variants" or "variant" or "mutation" or "mutations", and "meta" or "meta-analysis" or "system review". The articles included in our study had to meet three criteria: 1) they must have been evaluations of genetic polymorphisms of COPD using meta-analyses or pooled analyses; 2) they must have evaluated COPD susceptibility as the outcome (analyses of emphysema, chronic bronchitis, spirometry, etc. were excluded); and 3) they must have been published in English or Chinese. If there were two or more metaor pooled analysis concerning an identical association, only the one with the most cases was included. We extracted the following data from each study: gene, genetic polymorphism, odds ratio (OR) and 95%CI, number of studies, and number of cases and controls.
Associations were considered statistically significant when the reported 95%CI of OR excluded 1.0. For each statistically significant association we included, we calculated the FPRP using the Excel spreadsheet shared by Wacholder et al. (2004) . The FPRP value was determined by the P value, the given prior probability for the association, and the statistical power of the test. We calculated FPRP values for two levels of prior probabilities: at the level of 0.001, which would be similar to that expected for a candidate gene; and at the level of 0.000001, which would be similar to that expected for a random SNP. Therefore, a reader can evaluate the association according to their own judgment. Wacholder et al. (2004) suggested that the statistical power be estimated based on the ability to detect an OR of 1.5, when the alpha level was equal to the observed P value. Dong et al. (2008) found that for small ORs, an OR of 1.5 could be too conservative; so both ORs of 1.5 and 1.2 were used. FPRP values less than 0.2 indicate that the association is still significant for a given level of prior probability.
For true-positive polymorphisms, we further investigated the diagnostic value including sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic OR (DOR), and calculated area under the curve (AUC) to COPD using the Meta-DiSc software.
RESULTS
We identified 152 studies after initial research, among which 7 were not in English or Chinese and 31 were not about associations between genetic variants and COPD risk. One hundred and fourteen studies were left for full-text view. Among those, 47 were not meta-or pooled analyses and 6 did not take COPD risk as outcomes. Another 40 had fewer subjects than analyses concerning the same variant (Figure 1) . Ultimately, we included 21 published metaand pooled analyses, encompassing 23 different genes and 44 variant-COPD associations. Among the summary ORs of these 44 variants, 25 were reported to be significantly associated with the risk of COPD. Each included variant is shown in Table 1 . The FPRP values were calculated at two levels of prior probabilities. As shown in Table 2 , among the 25 associations, the FPRP values of 20 gene-variant/cancer associations were higher than 0.2 at both prior probabilities (0.001 and 0.000001), and these results are not regarded as noteworthy. At a prior probability level of 0.001 and a statistical power to detect an OR of 1.5, five associations were noteworthy (FPRP ≤ 0.2) for: 1) ADAM33 rs612709 (OR = 0.60; P value < 0.001); 2) CHRNA3/5 rs1051730 (OR = 1.14; P-value < 0.001); 3) CHRNA3/5 rs8034191 (OR = 1.29; P value < 0.001); 4) CHRNA3/5 rs16969968 (OR = 1.27; P value < 0.001); and 5) TGFB1 rs1800470 (OR = 0.73; P value = 0.002). At a very low prior probability (0.000001), four associations remained noteworthy: ADAM33 rs612709, CHRNA3/5 rs1051730, CHRNA3/5 rs8034191, and CHRNA3/5 rs16969968. The number was reduced to two (ADAM33 rs612709 and CHRNA3/5 rs1051730) when we calculated at a statistical power based on an OR of 1.2. Consistent with FPRP, those associations that were noteworthy at a very low level of prior probability were highly statistically significant. As shown in Table 3 , the pooled sensitivity, specificity, PLR, NLR, DOR, and AUC for the five true-positive variants were: 1) ADAM33 rs612709, 0. 
DISCUSSION
Increasing numbers of studies have suggested that certain candidate genes are involved in COPD risk, but individual studies have been limited by sample size and low reproducibility. Therefore, numerous meta-and pooled analyses have been published to assess the overall results of the association between the risk of COPD and genetic variants. Unfortunately, the results of meta-and pooled analyses can also contain false-positive findings. Liao et al. (2014) applied the FPRP methodology to evaluate nine positive associations between genetic variants and oral cancer risk included from meta-and pooled analyses, but none was noteworthy after calculation. However, no analogous study concerning COPD has been published. Therefore, we conducted the present FPRP analysis, and further investigated its diagnostic value. To our knowledge, this is the first and most comprehensive FPRP analysis conducted to assess the association between gene polymorphisms and COPD susceptibility.
In the present study, we found 32 variants reported to be positive in meta-and pooled analyses. Among those 32 mutations, 8 variants were found to be associated with decreased risk of COPD, while the other 24 variants were associated with an increased risk of COPD, and had ORs above 1.0. Five of the 32 polymorphisms were true-positives after we had calculated the FPRP: ADAM33 rs612709 (case + control: 1341 + 3359), CHRNA3/5 rs1051730 (case + control: 10,466 + 39,054), CHRNA3/5 rs803419 (case + control: 2652 + 2565), CHRNA3/5 rs16969968 (case + control: 1996 + 6463), and TGFB1 rs1800470 (case + control: 1482 + 3774). Among those, CHRNA3/5 rs1051730, CHRNA3/5 rs8034191, and CHRNA3/5 rs16969968 were associated with an increased risk of COPD, while ADAM33 rs612709 and TGFB1 rs1800470 were associated with decreased risk of COPD. ADAM proteins play a role in cell adhesion, cell signaling, cell fusion, and proteolysis (Primakoff and Myles, 2000) . They abound in smooth muscle cells and may play a part in airway hyperresponsiveness. Thus, variants in this gene may be involved in COPD risk. TGF-b1 plays a role in the deposition of extracellular matrix proteins such as collagens and fibronectin, as well as other facets of fibrosis. Researchers have discovered that the airway epithelium tissues of smokers with COPD express more TGF-b1 than smokers without COPD (Vignola et al., 1997) . Polymorphisms in the TGFB1 gene may, therefore, be related to COPD development. Moreover, the chromosome 15q25 region includes the CHRNA5-CHRNA3-CHRNB4 cluster, which encodes the subunits of alpha-nicotinic acetylcholine receptor (nAChR). These polymorphisms function by regulating the inflammatory response to smoking, and have an effect on nicotine dependence and smoking-related traits (Gwilt et al., 2007) .
For the five true-positives, the results of diagnostic accuracy meta-analyses suggested that these polymorphisms do not have a high diagnostic value, since all the PLRs were less than 2.0, and the AUCs were less than 0.7. The explanations for this might be as follows. First, the number of articles included in our study was limited, which may have influenced the diagnostic value of the test results. Second, the pathogenesis of COPD remains unclear, with both genetic and environmental determinants. There may be interaction between the environment and genetic susceptibility, and mutual interaction between different SNPs as opposed to one single polymorphism alone. Third, the role one SNP plays may differ in different ethnicities, genders, etc. Fourth, heterogeneity is an important issue when explaining the results of the present study. Although the results suggested that the diagnostic value of candidate gene associations was not high, we could not completely rule out the possibility that these variants are not risk factors for COPD.
Several issues should be considered when interpreting the results. First, although we made a concerted effort, we could not rule out the possibility that we left out some studies owing to language limitations and other reasons. Second, our data were extracted from published meta-and pooled analyses. Some original studies might have been missed, and selection bias cannot be completely avoided. Third, only published studies were included, so publication bias may have occurred.
In conclusion, we found only five gene polymorphisms that were truly associated with COPD risk after evaluation of the FPRP value. Although we did not find practical diagnostic biomarkers from candidate gene association studies, the method is still valuable, and the results may guide future studies on COPD. Future studies are needed to clarify the etiology and the role genetic factors play in COPD.
